对药物-疾病关系进行系统评估，以确定新型药物用途的潜在线索。
Systematic evaluation of drug-disease relationships to identify leads for novel drug uses.
作者信息
Chiang A P, Butte A J
机构信息
Department of Medicine, Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.
出版信息
Clin Pharmacol Ther. 2009 Nov;86(5):507-10. doi: 10.1038/clpt.2009.103. Epub 2009 Jul 1.
Abstract
Drug repositioning refers to the discovery of alternative uses for drugs--uses that are different from that for which the drugs were originally intended. One challenge in this effort lies in choosing the indication for which a drug of interest could be prospectively tested. We systematically evaluated a drug treatment-based view of diseases in order to address this challenge. Suggestions for novel drug uses were generated using a "guilt by association" approach. When compared with a control group of drug uses, the suggested novel drug uses generated by this approach were significantly enriched with respect to previous and ongoing clinical trials.
摘要
药物重新定位是指发现药物的其他用途——这些用途与药物最初的预期用途不同。这项工作面临的一个挑战在于选择可以对感兴趣的药物进行前瞻性测试的适应症。为了应对这一挑战，我们系统地评估了基于药物治疗的疾病观点。使用“关联有罪”方法生成了新药用途的建议。与药物用途对照组相比，通过这种方法生成的建议新药用途在先前和正在进行的临床试验方面显著富集。
相似文献
1
Systematic evaluation of drug-disease relationships to identify leads for novel drug uses.
Clin Pharmacol Ther. 2009 Nov;86(5):507-10. doi: 10.1038/clpt.2009.103. Epub 2009 Jul 1.
2
Learning lessons from drugs that have recently entered the market.
Drug Discov Today. 2011 May;16(9-10):398-411. doi: 10.1016/j.drudis.2011.03.003. Epub 2011 Mar 23.
3
Wrong questions, wrong answers? Are we getting the drugs we need?
Clin Pharmacol Ther. 2012 Mar;91(3):367-9. doi: 10.1038/clpt.2011.335.
4
Fragment-based lead discovery grows up.
Nat Rev Drug Discov. 2013 Jan;12(1):5-7. doi: 10.1038/nrd3926.
5
APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use.
Nat Rev Drug Discov. 2009 Nov;8(11):849-53. doi: 10.1038/nrd2981. Epub 2009 Aug 28.
6
What drives site performance in clinical trials?
Nat Rev Drug Discov. 2018 Jun;17(6):389-390. doi: 10.1038/nrd.2018.51. Epub 2018 Apr 20.
7
Requirements for a lead compound to become a clinical candidate.
BMC Neurosci. 2008 Dec 10;9 Suppl 3(Suppl 3):S7. doi: 10.1186/1471-2202-9-S3-S7.
8
Industry embraces virtual trial platforms.
Nat Rev Drug Discov. 2018 Apr 27;17(5):305-306. doi: 10.1038/nrd.2018.66.
9
Molecular topology as a novel approach for drug discovery.
Expert Opin Drug Discov. 2012 Feb;7(2):133-53. doi: 10.1517/17460441.2012.652083. Epub 2012 Jan 10.
10
Managing the challenge of chemically reactive metabolites in drug development.
Nat Rev Drug Discov. 2011 Apr;10(4):292-306. doi: 10.1038/nrd3408.
引用本文的文献
1
Adaptive multi-view learning method for enhanced drug repurposing using chemical-induced transcriptional profiles, knowledge graphs, and large language models.
J Pharm Anal. 2025 Jun;15(6):101275. doi: 10.1016/j.jpha.2025.101275. Epub 2025 Mar 21.
2
Drug repurposing: a promising drug discovery strategy for the treatment of emerging epidemic infectious disease.
Mol Divers. 2025 Jul 3. doi: 10.1007/s11030-025-11247-x.
3
Strategies for robust, accurate, and generalizable benchmarking of drug discovery platforms.
bioRxiv. 2024 Dec 16:2024.12.10.627863. doi: 10.1101/2024.12.10.627863.
4
Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.
CNS Neurol Disord Drug Targets. 2025;24(2):115-131. doi: 10.2174/0118715273329531240911075309.
5
Deep learning of multimodal networks with topological regularization for drug repositioning.
J Cheminform. 2024 Aug 23;16(1):103. doi: 10.1186/s13321-024-00897-y.
6
A comparative benchmarking and evaluation framework for heterogeneous network-based drug repositioning methods.
Brief Bioinform. 2024 Mar 27;25(3). doi: 10.1093/bib/bbae172.
7
Drug Repurposing: Insights into Current Advances and Future Applications.
Curr Med Chem. 2025;32(3):468-510. doi: 10.2174/0109298673266470231023110841.
8
A novel approach for predicting upstream regulators (PURE) that affect gene expression.
Sci Rep. 2023 Oct 30;13(1):18571. doi: 10.1038/s41598-023-41374-0.
9
Drug repurposing-a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA).
Front Cardiovasc Med. 2023 Jun 16;10:1156456. doi: 10.3389/fcvm.2023.1156456. eCollection 2023.
10
Finding melanoma drugs through a probabilistic knowledge graph.
PeerJ Comput Sci. 2017 Feb 13;3:e106. doi: 10.7717/peerj-cs.106. eCollection 2017.
本文引用的文献
1
Exploring the geometry of treatment networks.
Ann Intern Med. 2008 Apr 1;148(7):544-53. doi: 10.7326/0003-4819-148-7-200804010-00011.
2
Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs.
J Pharmacol Exp Ther. 2008 May;325(2):595-600. doi: 10.1124/jpet.108.136127. Epub 2008 Feb 5.
3
Drug-target network.
Nat Biotechnol. 2007 Oct;25(10):1119-26. doi: 10.1038/nbt1338.
4
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Blood. 2007 Oct 1;110(7):2674-84. doi: 10.1182/blood-2006-09-048033. Epub 2007 Jul 10.
5
Rare diseases, orphan drugs, and orphaned patients.
Mol Interv. 2006 Aug;6(4):186-91. doi: 10.1124/mi.6.4.2.
6
Drug repositioning: identifying and developing new uses for existing drugs.
Nat Rev Drug Discov. 2004 Aug;3(8):673-83. doi: 10.1038/nrd1468.
7
The Unified Medical Language System (UMLS): integrating biomedical terminology.
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D267-70. doi: 10.1093/nar/gkh061.
8
Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement.
Lupus. 2003;12(10):798-800. doi: 10.1191/0961203303lu450xx.
9
The price of innovation: new estimates of drug development costs.
J Health Econ. 2003 Mar;22(2):151-85. doi: 10.1016/S0167-6296(02)00126-1.
10
New drug development in the United States from 1963 to 1999.
Clin Pharmacol Ther. 2001 May;69(5):286-96. doi: 10.1067/mcp.2001.115132.
Zotero 插件